Novartis AG ADR NVS
News
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
Trending: Novartis Shares Climb on Guidance Lift
Novartis Raises Guidance on Profit, Sales Growth — Update
Novartis shares jump as drugmaker boosts outlook
Novartis Raises Guidance on Profit, Sales Growth
Novartis Gets Priority Review for Kidney Disease Treatment
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Trending: Novartis Begins Tender Offer for MorphoSys Shares
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Novartis Adjusts Manufacturing of Breast Cancer Drug Ribociclib